{"url_path":"/sec/rgnx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1590877/0001193125-26-222804-index.html","accession_number":"0001193125-26-222804","cik":"0001590877","ticker":"RGNX","issuer_name":"REGENXBIO Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1590877/0001193125-26-222804-index.html","primary_entity_key":"0001590877","primary_entity_name":"REGENXBIO Inc."},"word_count":357,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\n \n\n \n\n \n\n \n\nIncorporated by Reference\n\n \n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n \n\nForm\n\n \n\nExhibit\n\nNumber\n\n \n\nFiling Date\n\n \n\nFiled or\n\nFurnished\n\nHerewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  3.1\n\n \n\n[Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/0001590877/000156459021031957/rgnx-ex31_42.htm)\n\n \n\n8-K\n\n \n\n3.1\n\n \n\n6/7/21\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  3.2\n\n \n\n[Amended and Restated Bylaws](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-ex3_2.htm)\n\n \n\n10-K\n\n \n\n3.2\n\n \n\n3/5/26\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.1†\n\n \n\n[Settlement and Release Agreement dated March 18, 2026 between the Registrant and GlaxoSmithKline LLC](rgnx-ex10_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.2†\n\n \n\n[License Agreement dated August 16, 2018 between the Registrant and Emory University](rgnx-ex10_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.1\n\n \n\n[Certification of the Chief Executive Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002](rgnx-ex31_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n31.2\n\n \n\n[Certification of the Chief Financial Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002](rgnx-ex31_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.1\n\n \n\n[Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C. 1350](rgnx-ex32_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101\n\n \n\nThe following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 formatted in Inline XBRL (eXtensible Business Reporting Language):\n\n(i) Consolidated Balance Sheets\n\n(ii) Consolidated Statements of Operations and Comprehensive Income (Loss)\n\n(iii) Consolidated Statements of Stockholders’ Equity\n\n(iv) Consolidated Statements of Cash Flows\n\n(v) Notes to Consolidated Financial Statements\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n104\n\n \n\nThe cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 formatted in Inline XBRL (included in Exhibit 101)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n† Portions of this exhibit have been omitted.\n\nThe certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of REGENXBIO Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.\n\n41\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nREGENXBIO Inc.\n\n \n\n \n\n \n\nDated: May 14, 2026\n\n \n\n/s/ Curran Simpson\n\n \n\n \n\nCurran Simpson\n\n \n\n \n\nPresident and Chief Executive Officer\n\n(Principal Executive Officer)\n\n \n\nDated: May 14, 2026\n\n \n\n/s/ Mitchell Chan\n\n \n\n \n\nMitchell Chan\n\n \n\n \n\nChief Financial Officer\n\n(Principal Financial Officer and Principal Accounting Officer)\n\n \n\n42"}